Dermatology

New Biologics Are Skewing Exclusivity Periods Longer, Study Says

July 14th 2020

By Tony Hagen

The rise of biologics as a class of prescription spending is fueling a trend toward longer exclusivity periods, which ultimately makes access more remote, authors of a new study said.

Looking Back, UK Patients Unhappy With Adalimumab Biosimilar Switch

June 24th 2020

By Allison Inserro

Article

The UK results show how challenging switching to a biosimilar can be, according to patient groups.

Revance, Mylan to File Application for Botox Biosimilar

June 1st 2020

By Tony Hagen

Article

After some delay, Revance and Mylan have decided to push forward with an FDA application for an onabotulinumtoxinA (Botox) biosimilar.

Humira Sales Grow as Competition Heats Up

May 4th 2020

By Tony Hagen

Article

After 17 years on the US market, Humira (adalimumab) proves it can still generate high sales, but competition from biosimilars is growing.

WellDyne Executive Says Formulary Exclusions Are on the Rise

April 23rd 2020

By Tony Hagen

Article

Jeenal Patel, PharmD, BCGP, a formulary manager for WellDyne, said pharmacy benefit managers (PBMs) and employers are increasingly turning to formulary exclusions to control the rising cost of drugs.

AMCP Posters Demonstrate Value of Biosimilars

April 20th 2020

By Skylar Jeremias

Article

Posters presented at the Academy of Managed Care Pharmacy (AMCP) eLearning Days meeting this week from April 20 to 24 reveal important data on biosimilar utilization management, switching, and affordability.

AbbVie Patents Are Costly for Healthcare Consumers

April 11th 2020

By Tony Hagen

Article

The Danish medical system saved 82.8% on adalimumab by switching almost all patients from the reference product to biosimilars, but such a benefit for the US healthcare system may not be possible, according to a new study.

BiosanaPharma Reports Positive Phase 1 Results for Omalizumab Biosimilar

April 9th 2020

By Tony Hagen

Article

With positive phase 1 study results and a manufacturing process that may cut costs significantly, BiosanaPharma hopes its omalizumab biosimilar candidate will have an edge on the worldwide market.

NeuClone Completes Early Testing for Psoriasis Biosimilar

April 8th 2020

By The Center for Biosimilars

Article

NeuClone said phase 1 patient monitoring and blood sampling has been completed for its ustekinumab biosimilar candidate, which is targeted at the $6.6 billion in annual revenue earned by Stelara, a Janssen Pharmaceutical Companies product.

Alvotech Hf and DKSH Announce Plans to Bring an Adalimumab Biosimilar to Market

March 26th 2020

By The Center for Biosimilars

Article

Alvotech Hf and DSH hope to get an adalimumab biosimilar approved in the United States, Europe, and selected Southeast Asia markets.